Tacrine (HCl)

A centrally acting reversible cholinesterase inhibitor, which is used to treat mild to moderate dementia of Alzheimer's type. It improves cognitive (the operation of the mind by which we become aware of the objects of thoughts or perception) performance.

Tacrine (HCl) is primarily indicated in conditions like Alzheimer's disease, Dementia, Respiratory depression.

Tacrine (HCl) is contraindicated in conditions like Anesthesia, Cardiovascular disease, Hypersensitivity, GI diseases, Pulmonary disease.

The severe or irreversible adverse effects of Tacrine (HCl), which give rise to further complications include Transaminase elevation. The signs and symptoms that are produced after the acute overdosage of Tacrine (HCl) include Bradycardia, Hypotension, Nausea, Vomiting, Convulsions, Sweating, Muscular weakness, Increased salivation. The symptomatic adverse reactions produced by Tacrine (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Flatulence, Nausea, Vomiting, Anorexia, Diarrhea, Constipation, Abdominal pain, Bradycardia, Skin Rash, Dyspepsia, Change in BP.

It should be used only if clearly needed during pregnancy. It should be used with caution in patients with asthma, seizure disorder, epilepsy, heart disease such as hypertension, bradycardia, recent myocardial infraction, thyroid disorders, intestinal disorders, ulcers, urinary problems, impaired liver function or who have a history of such impairment or if have any allergy especially to bromides. Large dose by mouth should be avoided in condition where there may be increase absorption from the gastrointestinal tract. Serum-alanine aminotransferase concentrations should be monitored in patients receiving continuous treatment with Tacrine. Monitoring should be carried out every other week for at least the first first 16 weeks of therapy, followed by monthly for 2 months and then every 3 months thereafter. Weekly monitoring is recommended in patients with elevated aminotransferase levels that are greater than twice the upper limit of the normal range. If sign of liver involvement worsen, the dose should be reduced or withdrawn. Tacrine should be taken on an empty stomach to improve absorption. The initial dose is given for a minimum of 6 weeks. Dosage should not be increased during this period because the potential exists for a delay in onset of increased liver enzyme concentration. Serum-alanine aminotransferase concentrations should be monitored regularly and if there is no significant increase doses may be increased.

Drug should not be given to Pregnant Mothers, Cardiac / Hypertensive Patients, and patients suffering from Liver Malfunction. If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

10 mg (10 (10)) 6 hourly PO — For 6 weeks. Scraped Dose — Serum transaminase levels (specifically ALT/SGPT) should be monitored in patients given Cognex® (see WARNINGS: Liver Injury).

No child dosage information is recorded for this medicine yet.

No neonatal dosage information is recorded for this medicine yet.

Tacrine (HCl) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementBethanechol (Cl)Cimetidine (HCl)ClemastineFluvoxamine (Maleate)GlycopyrrolateHydrocortisoneOxymorphoneTacrine antagonizes the respiratory-depressant and sedative effects of morphine without altering its analgesic effects. The mechanism may be related both to the cholinergic effects of tacrine and to alterations in the metabolic fate of morphine. Other narcotic analgesics may participate in this interaction as well.MinorPantothenic AcidPantothenic Acid may increase the effects of Tacrine (HCl).ParegoricTacrine antagonizes the respiratory-depressant and sedative effects of morphine without altering its analgesic effects. The mechanism may be related both to the cholinergic effects of tacrine and to alterations in the metabolic fate of morphine. Other narcotic analgesics may participate in this interaction as well.MinorTheophylline These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Caps Store at room temperature. Protect from Moisture.